Experimental combo aims to tackle Hard-to-Treat prostate cancer
NCT ID NCT05743621
First seen Nov 21, 2025 · Last updated Jun 23, 2026 · Updated 24 times
Summary
This early-stage trial tests a new drug called TVB-2640 combined with the standard drug enzalutamide (Xtandi) in 30 men whose prostate cancer has spread and stopped responding to hormone therapy. The main goal is to find the safest dose of TVB-2640 when used with enzalutamide and to track any side effects. Participants will be followed for about 12 to 24 months.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATIC NEOPLASMS, CASTRATION-RESISTANT are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Weill Cornell Medicine/NewYork-Presbyterian Hospital
RECRUITINGNew York, New York, 10021, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
TVB-2640 (a fatty acid synthase inhibitor) combined with enzalutamide (Xtandi)
What this could lead to
If this combination proves safe, it could lead to a new treatment option for men with advanced prostate cancer that has stopped responding to hormone therapy.
What could go wrong
This is a very early Phase 1 trial with only 30 participants, focused on safety and dosing. It is too small and early to know if the combination actually works against cancer.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.